Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Fusion Antibodies Revenue Falls: Can Trading Stabilise?

Fusion Antibodies (LSE:FAB) is included in this fresh batch of UK corporate-news coverage for 15 October 2026.

Ankur Sharma | 15 October 2026

Scancell Funding Update Puts Clinical Progress and Dilution in Focus

Scancell Holdings (LSE:SCLP) is included in this fresh batch of UK corporate-news coverage for 15 October 2026.

Ankur Sharma | 15 October 2026

SkinBioTherapeutics Office Change Is Not the Catalyst—Commercial Progress Is

SkinBioTherapeutics (LSE:SBTX) is included in this fresh batch of UK corporate-news coverage for 15 October 2026.

Ankur Sharma | 15 October 2026

Why Spire Healthcare's Days in the FTSE 250 May Be Numbered After a £1bn Agreed Bid

After more than a year of strategic review, failed talks and shareholder pressure, Spire Healthcare (LSE: SPI) appears to be approaching the end of its life as a listed company. The FTSE 250 group has agreed to a takeover by Tulip UK Bidco, a …

Ishan Mudgal | 15 October 2026

What Oxford BioMedica's Durham Ramp-Up Means for Its FTSE 250 Recovery Story

The gene and cell therapy contract manufacturer has spent the past two months trying to rebuild confidence after a difficult summer. On 7 August, Oxford BioMedica (LSE: OXB) told the market that full-year 2026 revenue would come in at£180m to £200mon a constant-currency basis, …

Ishan Mudgal | 15 October 2026

How Oxford Nanopore Is Rebuilding Confidence Among FTSE 250 Investors After a Volatile Summer

Oxford Nanopore Technologies plc (LSE: ONT) has given investors a turbulent ride in 2026. The FTSE 250 life sciences company, which develops portable DNA and RNA sequencing devices, saw its shares slump in July after warning on first-half revenue, only to rally strongly in …

Ishan Mudgal | 15 October 2026

Why Ondine Biomedical (LSE:OBI) Has Paused Trading on the FTSE AIM All Share Index to Raise Funds

Ondine develops light-activated antimicrobial therapies, which it calls photodisinfection, to prevent and treat infections. Its lead product, Steriwave, is used for nasal decolonisation to reduce the risk of infection in surgical and intensive care patients. It is authorised in Canada, the UK and certain …

Ankur Sharma | 15 October 2026

Why OptiBiotix Health (LSE:OPTI) Is Betting on a New Sweetener on the FTSE AIM All Share Index

OptiBiotix is a life sciences company developing products that aim to reduce hunger and cravings, support the gut microbiome and replace sugar with sweet fibres. Its first-generation products include SlimBiome, used in weight management, and WellBiome, aimed at gut and digestive health. SweetBiotix is …

Ankur Sharma | 15 October 2026

Arecor Insulin Patents Strengthen the IP Case, but Commercial Proof Is Next

Arecor Therapeutics (LSE:AREC) is in focus on 15 October 2026 following a fresh corporate development.

Ankur Sharma | 15 October 2026

What Fusion Antibodies (LSE:FAB) Results Reveal for Its Place on the FTSE AIM All Share Index

Fusion Antibodies is a contract research organisation focused on antibody engineering. It provides services such as antibody humanisation, sequencing and stable cell line development to pharmaceutical and biotechnology clients, many of them in North America. In recent years it has been building proprietary technology, …

Ankur Sharma | 15 October 2026
Support

Hi! How can we help you today?

Loading…